Related Experiment Video

Updated: Feb 28, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.9K

Nintedanib in systemic sclerosis-associated interstitial lung disease: real-world cohort study on tolerability and

Punchalee Kaenmuang1, Nina R Goldman2, Arthihai Srirangan3

  • 1Interstitial Lung Disease Unit, Royal Brompton Hospital, Guy's and St Thomas' National Health Service Foundation Trust, London; Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, UK; and Respiratory and Respiratory Critical Care Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand. punchalee.k@psu.ac.th.

Clinical and Experimental Rheumatology
|February 27, 2026
PubMed
Abstract

Insights

Nintedanib treatment interruptions are common in systemic sclerosis-associated interstitial lung disease (SSc-ILD) patients, particularly older individuals and those with low BMI. Close monitoring and supportive care are crucial for managing side effects and maintaining treatment continuity.

Area of Science:

  • Pulmonology
  • Rheumatology
  • Pharmacology

Background:

  • Nintedanib is approved for systemic sclerosis-associated interstitial lung disease (SSc-ILD).
  • Tolerability and treatment interruptions are potential concerns in SSc-ILD patients receiving nintedanib.

Purpose of the Study:

  • To evaluate the tolerability of nintedanib in SSc-ILD patients.
  • To identify factors associated with treatment interruptions and permanent discontinuation.

Main Methods:

  • A multicentre study involving 63 SSc-ILD patients treated with nintedanib.
  • Analysis of treatment interruptions, reasons for interruption, and time to first interruption using logistic and Cox regression.
  • Comparison of weight changes before and after nintedanib initiation.

Main Results:

  • 51% of patients experienced nintedanib interruptions, most commonly due to diarrhea, nausea/vomiting, and weight loss.
  • Older age and a body mass index (BMI) <18.5 kg/m2 were independently associated with treatment interruptions.
  • Permanent discontinuation occurred in 20.6% of patients, with no significant predictors identified.
  • Significant weight loss was observed after nintedanib initiation compared to the period before treatment.

Conclusions:

  • Adverse effects frequently lead to nintedanib treatment interruptions in SSc-ILD patients.
  • Older age and lower BMI predict treatment interruptions, emphasizing the need for individualized management.
  • Most patients can resume nintedanib, underscoring the importance of supportive care for side effect management and treatment adherence.

More Related Videos

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer11:31

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer

Published on: May 20, 2016

11.3K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
511
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
3.2K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
953
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.0K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
192
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
288